Miguel Vicco, PhD MD

GSK, Belgium

Disclosure(s): GlaxoSmithKline Biologicals SA: Employee, Stocks/Bonds

Poster(s):

• 119 - Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis at 6 Months after Vaccination
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET